Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 8, 2011, Pages 935-948

  De Wildt, Saskia N ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

child; drug metabolism; fetus; ontogeny; pharmacodynamics; pharmacogenetics; pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALCOHOL DEHYDROGENASE; ARACHIDONIC ACID; CAFFEINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE; DIPHENHYDRAMINE; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; IBUPROFEN; MELATONIN; METHADONE; MIDAZOLAM; MORPHINE; OXIDOREDUCTASE; TACROLIMUS; TRAMADOL;

ADENOTONSILLECTOMY; BLOOD VESSEL TONE; CHILD; CLINICAL PRACTICE; COMORBIDITY; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; GROWTH HORMONE DEFICIENCY; HETEROZYGOTE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; LONG QT SYNDROME; NEWBORN; PATENT DUCTUS ARTERIOSUS; PERINATAL PERIOD; PLASMA CLEARANCE; POSTNATAL DEVELOPMENT; PREMATURITY; PROTEIN EXPRESSION; REVIEW; SEDATION; SICKLE CELL; SINGLE DRUG DOSE; SLEEP; SLEEP DISORDER; SUDDEN INFANT DEATH SYNDROME; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

ALCOHOL DEHYDROGENASE; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FETAL DEVELOPMENT; GENETIC VARIATION; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; METABOLIC DETOXICATION, DRUG; OXYGENASES; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE;

EID: 79960521621     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.577739     Document Type: Review

References (142)

1. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1:447-71
2. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67 (Pubitemid 37122329)
3. Holford N. Dosing in children. Clin Pharmacol Ther 2010;87:367-70
4. Sutherland JM. Fatal cardiovascular collaps of infants receiving large amounts of chloramphenicol. AMA J Dis Child 1959;97:761-7
5. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. A physiological explanation of its toxicity when given in excessive doses. N Engl J Med 1960;262:787-94
6. Chen M, LeDuc B, Kerr S, et al. Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Drug Metab Dispos 2010;38:368-75
7. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008;118:250-67
8. de Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today 2009;14:6-15
9. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998;57:107-16 (Pubitemid 28063210)
10. Committee HCPCAN. Human Cytochrome P450 (CYP) Allele Nomenclature. Available from: http://www.cypalleles.ki.se/. [Cited 12 January 2010]
11. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci 2011;120:1-13
12. Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 1999;29:847-57 (Pubitemid 29454397)
13. Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 1996;18:254-62 (Pubitemid 26159576)
14. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-90
15. Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995;39:321-6
16. Braam W, van Geijlswijk I, Keijzer H, et al. Loss of response to melatonin treatment is associated with slow melatonin metabolism. J Intellect Disabil Res 2010;54:547-55
17. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998;251:893-8 (Pubitemid 28108986)
18. Cazeneuve C, Pons G, Rey E, et al. Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br J Clin Pharmacol 1994;377:405-12 (Pubitemid 24197132)
19. Pariente-Khayat A, Pons G, Rey E, et al. Caffeine acetylator phenotyping during maturation in infants. Pediatr Res 1991;29:492-5
20. Blake MJ, Abdel-Rahman SM, Pearce RE, et al. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 2006;60:717-23 (Pubitemid 44789515)
21. Charles BG, Townsend SR, Steer PA, et al. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit 2008;30:709-16
22. Akinyinka OO, Sowunmi A, Honeywell R, et al. The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. Eur J Clin Pharmacol 2000;56:153-8 (Pubitemid 30341390)
23. Kennedy MJ, Davis DA, Smith N, et al. Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther 2008;84:674-8
24. Kennedy MJ, Davis DA, Smith N, et al. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement. Clin Ther 2008;30:1687-99
25. Kennedy MJ, Scripture CD, Kashuba AD, et al. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin Pharmacol Ther 2004;75:163-71 (Pubitemid 38314865)
26. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004;18:2391-400 (Pubitemid 40065906)
27. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000;28:1222-30
28. Granvil CP, Madan A, Sharkawi M, et al. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999;27:533-41 (Pubitemid 29177648)
29. Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363-74 (Pubitemid 351304229)
30. Chang TK, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-37 (Pubitemid 23360263)
31. Croom EL, Stevens JC, Hines RN, et al. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 2009;78:184-90
32. Hussain T, Ewer AK. Maternal methadone may cause arrhythmias in neonates. Acta Paediatr 2007;96:768-9 (Pubitemid 46656109)
33. Bunten H, Liang WJ, Pounder DJ, et al. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010;88:383-9
34. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300 (Pubitemid 36734384)
35. ter Heine R, Scherpbier HJ, Crommentuyn KM, et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008;13:779-87
36. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther 2008;83:300-6
37. Rokitta D, Fuhr U. Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Curr Drug Metab 2010;11:153-61
38. Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995;58:412-17
39. Leemann T, Kondo M, Zhao J, et al. The biotransformation of NSAIDs: a common elimination site and drug interactions. Schweiz Med Wochenschr 1992;122:1897-9
40. Miners JO, Coulter S, Tukey RH, et al. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996;51:1003-8
41. Veronese ME, Mackenzie PI, Doecke CJ, et al. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-18
42. Kunze KL, Wienkers LC, Thummel KE, et al. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996;24:414-21
43. Sohn DR, Kwon JT, Kim HK, et al. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4?- hydroxylation phenotype status. Clin Pharmacol Ther 1997;61:574-82
44. Yasumori T, Nagata K, Yang SK, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993;3:291-301
45. Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998;26:609-16 (Pubitemid 28345843)
46. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990;47:79-85 (Pubitemid 20041214)
47. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4?-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997;62:619-28 (Pubitemid 28068065)
48. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308:965-74 (Pubitemid 38263972)
49. Treluyer JM, Benech H, Colin I, et al. Ontogenesis of CYP2C-dependent arachidonic acid metabolism in the human liver: relationship with sudden infant death syndrome. Pediatr Res 2000;47:677-83 (Pubitemid 30249859)
50. Beurton F, Gueret G, Horisberger M, et al. Transcriptional activation of CYP2C, MxA and Fas in sudden infant death syndrome. Int J Mol Med 1999;3:33-9
51. Gregoire N, Desfrere L, Roze JC, et al. Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. J Clin Pharmacol 2008;48:1460-8
52. Durrmeyer X, Hovhannisyan S, Medard Y, et al. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? PLoS One 2010;5:e12329
53. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997;54:33-41 (Pubitemid 27353220)
54. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000;68:541-55
55. Ruud E, Holmstrom H, Bergan S, et al. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Pediatr Blood Cancer 2008;50:710-13 (Pubitemid 351155871)
56. Kondo T, Kaneko S, Otani K, et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 1992;33:172-7
57. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005;44:441-66 (Pubitemid 40733732)
58. Ward RM, Kearns GL, Tammara B, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 17 September 2010. [Epub ahead of print]
59. Pettersen G, Mouksassi MS, Theoret Y, et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Br J Clin Pharmacol 2009;67:216-27
60. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 2010;38:894-7
61. Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol 2010;66:555-61
62. Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol 2010;66:555-61
63. Leeder JS, Kearns GL, Spielberg SP, et al. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010;50:1377-87
64. Akutsu T, Kobayashi K, Sakurada K, et al. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 2007;35:72-8 (Pubitemid 46036479)
65. Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41:23-6
66. Perault MC, Bouquet S, Bertschy G, et al. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment. Therapie 1991;46:1-3
67. Llerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4
68. Lennard MS, Tucker GT, Silas JH, et al. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986;16:435-47 (Pubitemid 16076722)
69. Jacqz-Aigrain E, Cresteil T. Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies. Dev Pharmacol Ther 1992;18:161-8 (Pubitemid 23159028)
70. Stevens JC, Marsh SA, Zaya MJ, et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 2008;36:1587-93
71. Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007;81:510-16 (Pubitemid 46452306)
72. Johnson TN, Tucker GT, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the First Year of Life. Clin Pharmacol Ther 2007;83:670-1
73. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr Anaesth 2011;21:266-73
74. Merenstein D, Diener-West M, Halbower AC, et al. The trial of infant response to diphenhydramine: the TIRED study - a randomized, controlled, patient-oriented trial. Arch Pediatr Adolesc Med 2006;160:707-12
75. Roehrs T, Zwyghuizen-Doorenbos A, Roth T. Sedative effects and plasma concentrations following single doses of triazolam, diphenhydramine, ethanol and placebo. Sleep 1993;16:301-5 (Pubitemid 23176286)
76. Albers S, Meibohm B, Mir TS, et al. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol 2008;65:511-22 (Pubitemid 351365127)
77. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31 (Pubitemid 40051906)
78. Brousseau DC, McCarver DG, Drendel AL, et al. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 2007;150:623-6 (Pubitemid 46755803)
79. Williams DG, Patel A, Howard RF. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 2002;89:839-45 (Pubitemid 35460521)
80. Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid- metabolism genotype, and postoperative death. N Engl J Med 2009;361:827-8
81. Madadi P, Hildebrandt D, Gong IY, et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 2010;126:e986-9
82. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368:704 (Pubitemid 44223697)
83. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver micrsomes of 30 japanese and 30 caucasians. J Pharmacol Exp Ther 1994;270:414-23 (Pubitemid 24229655)
84. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-72 (Pubitemid 38499965)
85. Shimada T, Yamazaki H, Mimura M, et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 1996;24:515-22 (Pubitemid 26143771)
86. Lacroix D, Sonnier M, Monion A, et al. Expression of CYP3A in the liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997;247:625-34 (Pubitemid 27308642)
87. Leeder JS, Gaedigk R, Marcucci KA, et al. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 2005;314:626-35 (Pubitemid 41043843)
88. Sim SC, Edwards RJ, Boobis AR, et al. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics 2005;15:625-31 (Pubitemid 41113335)
89. Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003;307:573-82 (Pubitemid 37310671)
90. Hakkola J, Raunio H, Purkunen R, et al. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 2001;80:193-201 (Pubitemid 34701548)
91. Kharasch ED, Thummel KE, Watkins PB. CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol Interv 2005;5:151-3 (Pubitemid 41018270)
92. de Wildt SN, Berns MJ, van den Anker JN. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study. Ther Drug Monit 2007;29:225-30 (Pubitemid 46716190)
93. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001;70:525-31 (Pubitemid 34008409)
94. Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994;56:615-25 (Pubitemid 124006569)
95. Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001;41:1359-69 (Pubitemid 33104904)
96. Smith MT, Eadie MJ, O?Rourke Brophy T. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981;19:271-178
97. Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth 2010;21:302-8
98. Jacqz-Aigrain E, Daoud P, Burtin P, et al. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet 1994;344:646-50 (Pubitemid 24274309)
99. de Wildt SN, de Hoog M, Vinks AA, et al. Pharmacodynamics of midazolam in pediatric intensive care patients. Ther Drug Monit 2005;27:98-102 (Pubitemid 40189981)
100. Hartwig S, Roth B, Theisohn M. Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. Eur J Pediatr 1991;150:784-8
101. de Gast-Bakker DA, van der Werff SD, Sibarani-Ponsen R, et al. Age is of influence on midazolam requirements in a paediatric intensive care unit. Acta Paediatr 2007;96:414-17 (Pubitemid 46442532)
102. Vet NJ, de Hoog M, Tibboel D, et al. The effect of critical illness and inflammation on midazolam therapy in children. Pediatr Crit Care Med 2010. [Epub ahead of print]
103. de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003;31:1952-8 (Pubitemid 36900749)
104. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol 1991;41:355-7
105. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989;37(3):267-72 (Pubitemid 19242733)
106. de Wildt SN, El-Brojeni PY, Reydman E, et al. Effect of age and genotype on tacrolimus dosing requirements in the immediate post-transplant period in pediatric kidney recipients. Clin Pharmacol Ther 2010;87:S67-7
107. Strolin Benedetti M, Whomsley R, Baltes E. Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2006;2:895-921 (Pubitemid 44911539)
108. Sultatos LG, Pastino GM, Rosenfeld CA, et al. Incorporation of the genetic control of alcohol dehydrogenase into a physiologically based pharmacokinetic model for ethanol in humans. Toxicol Sci 2004;78:20-31 (Pubitemid 38351420)
109. Smith M, Hopkinson DA, Harris H. Developmental changes and polymorphism in human alcohol dehydrogenase. Ann Hum Genet 1971;34:251-71
110. Tran MN, Wu AH, Hill DW. Alcohol dehydrogenase and catalase content in perinatal infant and adult livers: potential influence on neonatal alcohol metabolism. Toxicol Lett 2007;169:245-52 (Pubitemid 46436373)
111. During R, Wegener R, Kading U, et al. Tocolysis with ethanol-effects on the ethanol content of the blood in the mother and neonate. Zentralbl Gynakol 1990;112:231-5 (Pubitemid 20105563)
112. Chikwava K, Lower DR, Frangiskakis SH, et al. Acute ethanol intoxication in a 7-month-old infant. Pediatr Dev Pathol 2004;7:400-2 (Pubitemid 39145714)
113. van Ooij C, Snyder RC, Paeper BW, et al. Temporal expression of the human alcohol dehydrogenase gene family during liver development correlates with differential promoter activation by hepatocyte nuclear factor 1, CCAAT/enhancer-binding protein alpha, liver activator protein, and D-element-binding protein. Mol Cell Biol 1992;12:3023-31
114. Hisamuddin IM, Yang VW. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 2007;8.635-43 (Pubitemid 46939588)
115. Dolphin CT, Cullingford TE, Shephard EA, et al. Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. Eur J Biochem 1996;235:683-9 (Pubitemid 26060969)
116. Yanni SB, Annaert PP, Augustijns P, et al. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos 2010;38:25-31
117. de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999;36:439-52 (Pubitemid 29317491)
118. Allegaert K, Vanhaesebrouck S, Verbesselt R, et al. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 2009;31:411-15
119. Zaya MJ, Hines RN, Stevens JC. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 2006;34:2097-101 (Pubitemid 44837771)
120. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002;50:259-65 (Pubitemid 34087942)
121. Miyagi SJ, Collier AC. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos 2007;35:1587-92 (Pubitemid 47296052)
122. Thompson PA, Gupta M, Rosner GL, et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children?s oncology group. Cancer Chemother Pharmacol 2008;62:1027-37
123. Sakaguchi S, Garcia-Bournissen F, Kim R, et al. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Arch Dis Child 2009;94:981-2
124. Knibbe CA, Krekels EH, van den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009;48:371-85
125. Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008;101:680-9
126. Bouwmeester NJ, Hop WC, van Dijk M, et al. Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med 2003;29:2009-15 (Pubitemid 37487137)
127. Johnson TN, Tanner MS, Taylor CJ, et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001;51:451-60 (Pubitemid 32852983)
128. Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005;33:1603-7 (Pubitemid 41539956)
129. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002;53:390-2 (Pubitemid 34415590)
130. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999;39:454-61 (Pubitemid 29356465)
131. Aleksa K, Ito S, Koren G. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. J Lab Clin Med 2004;143:159-62 (Pubitemid 38352536)
132. Aleksa K, Halachmi N, Ito S, et al. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 2004;144:285-93 (Pubitemid 40018015)
133. Aleksa K, Matsell D, Krausz K, et al. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr Nephrol 2005;20:872-85 (Pubitemid 40909254)
134. Ince I, de Wildt SN, Tibboel D, et al. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today 2009;14:316-20
135. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009;24:25-36
136. Pons G, Blais JC, Rey E, et al. Maturation of caffeine N-demethylation in infancy: a study using the 13CO2 breath test. Pediatr Res 1988;23:632-6
137. Tserng KY, Takieddine FN, King KC. Developmental aspects of theophylline metabolism in premature infants. Clin Pharmacol Ther 1983;33:522-8 (Pubitemid 13093774)
138. Alam SN, Roberts RJ, Fischer LJ. Age-related differences in salicylamide and acetaminophen conjugation in man. J Pediatr 1977;90:130-5 (Pubitemid 8015655)
139. Herd B, Wynne H, Wright P, et al. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions. Br J Clin Pharmacol 1991;32:768-70
140. Filler G. Optimization of immunosuppressive drug monitoring in children. Transplant Proc 2007;39:1241-3 (Pubitemid 46764888)
141. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003;29:980-4 (Pubitemid 36783172)
142. Ceelie I, van der Starre C, Tibboel D, et al. Evaluation of drug formularies for pediatric intensive care. Pediatr Crit Care Med 2011;12:e14-19